UPDATE: Actinium Pharmaceuticals Says Iomab-b Remains The Only Targeted Conditioning Treatment In Clinical Trials With The Potential To Increase Access To And Improve Outcomes Of Bone Marrow Transplant
Benzinga Newsdesk